Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.94
-0.23 (-2.82%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Fulcrum Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Net Income
-74.88-9.73-97.34-109.87-80.85
Upgrade
Depreciation & Amortization
1.391.592.172.412.52
Upgrade
Loss (Gain) From Sale of Investments
-2.95-4.39-5.990.150.67
Upgrade
Stock-Based Compensation
12.4714.5514.813.3511.07
Upgrade
Other Operating Activities
----0-
Upgrade
Change in Accounts Receivable
2.1-1.56-0.313.41-1.11
Upgrade
Change in Accounts Payable
0.43-1.59-0.85-1.180.97
Upgrade
Change in Unearned Revenue
---0.93-3.78-13.17
Upgrade
Change in Other Net Operating Assets
1.39-1.1-2.52-1.551.41
Upgrade
Operating Cash Flow
-60.07-2.22-90.97-97.05-78.48
Upgrade
Capital Expenditures
-0.31-0.28-0.51-1.96-1.71
Upgrade
Investment in Securities
31.0332.51-36.1814.38-127.96
Upgrade
Investing Cash Flow
30.7232.23-36.6912.41-129.67
Upgrade
Long-Term Debt Repaid
-----0.02
Upgrade
Net Debt Issued (Repaid)
-----0.02
Upgrade
Issuance of Common Stock
168.672.75118.1284.32186.53
Upgrade
Financing Cash Flow
168.672.75118.1284.32186.51
Upgrade
Net Cash Flow
139.3232.76-9.54-0.31-21.64
Upgrade
Free Cash Flow
-60.38-2.5-91.47-99.01-80.19
Upgrade
Free Cash Flow Margin
--3.12%-3261.07%-1561.23%-418.47%
Upgrade
Free Cash Flow Per Share
-0.95-0.04-1.49-2.20-2.27
Upgrade
Levered Free Cash Flow
-33.92-2.08-56.72-58.12-47.54
Upgrade
Unlevered Free Cash Flow
-33.92-2.08-56.72-58.12-47.54
Upgrade
Change in Working Capital
3.91-4.25-4.61-3.09-11.89
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.